David Lewis
Stock Analyst at Morgan Stanley
(2.83)
# 1,694
Out of 5,180 analysts
271
Total ratings
69.77%
Success rate
10.56%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $127 → $137 | $102.67 | +33.44% | 25 | Jul 15, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $209.84 | +42.97% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $157.23 | +74.90% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $62.80 | +44.90% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $3.84 | +18,650.00% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $16.80 | +495.24% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $99.41 | -84.91% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $1.29 | +2,225.58% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $75.59 | -0.78% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $25.37 | +77.37% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $56.36 | +6.46% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $86.16 | -4.83% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $119.61 | +260.34% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $86.65 | +77.73% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $12.63 | +216.71% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $80.08 | +68.58% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $328.59 | -14.79% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $460.99 | -38.18% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $9.13 | +108.11% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $118.02 | -20.35% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $75.35 | +4.84% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $90.42 | +99.07% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $244.44 | -23.50% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $14.01 | +221.20% | 5 | Dec 15, 2020 |
Abbott Laboratories
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $127 → $137
Current: $102.67
Upside: +33.44%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $209.84
Upside: +42.97%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $157.23
Upside: +74.90%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $62.80
Upside: +44.90%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $3.84
Upside: +18,650.00%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $16.80
Upside: +495.24%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $99.41
Upside: -84.91%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $1.29
Upside: +2,225.58%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $75.59
Upside: -0.78%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $25.37
Upside: +77.37%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $56.36
Upside: +6.46%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $86.16
Upside: -4.83%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $119.61
Upside: +260.34%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $86.65
Upside: +77.73%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $12.63
Upside: +216.71%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $80.08
Upside: +68.58%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $328.59
Upside: -14.79%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $460.99
Upside: -38.18%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $9.13
Upside: +108.11%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $118.02
Upside: -20.35%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $75.35
Upside: +4.84%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $90.42
Upside: +99.07%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $244.44
Upside: -23.50%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $14.01
Upside: +221.20%